Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Technical aspects and clinical applications of measuring <i>BCR‐ABL1</i> transcripts number in chronic myeloid leukemia

19 May 2009

Abstract excerpt

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a triphasic clinical course, the morphologic expansion of a terminally differentiated myeloid cell and the presence of the BCR-ABL1 fusion gene, the hallmark of CML. The fusion gene is usually, but not always, associated with a Philadelphia chromosome, the result of a reciprocal exchange of genetic material between chromosome 22 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19544476
DOI: 10.1002/ajh.21457

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Technical aspects and clinical applications of measuring <i>BCR‐ABL1</i> transcripts number in chronic myeloid leukemiaPMID 19544476Read ↗

A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes.Semantic proximity Read ↗

Genomic<i>BCR</i>‐<i>ABL1</i>breakpoints in pediatric chronic myeloid leukemiaSemantic proximity Read ↗

Molecular monitoring of chronic myeloid leukemia: present and future.Semantic proximity Read ↗

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent AdvancesSemantic proximity Read ↗

Molecular monitoring in patients with chronic myelogenous leukemia.Semantic proximity Read ↗

Present and future of molecular monitoring in chronic myeloid leukaemia.Semantic proximity Read ↗

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.Semantic proximity Read ↗

Laboratory tools for diagnosis and monitoring response in patients with chronic myeloid leukemia.Semantic proximity Read ↗

Guidelines for the measurement of <i>BCR‐ABL1</i> transcripts in chronic myeloid leukaemiaSemantic proximity Read ↗

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.Semantic proximity Read ↗

Chronic myeloid leukemia: molecular monitoring in clinical practice.Semantic proximity Read ↗

[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.